NCT05526157View on ClinicalTrials.gov

An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice

CompletedOBSERVATIONAL

Enrollment

50,000

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

September 5, 2024

Study Completion Date

September 5, 2024

Conditions

Chronic Kidney DiseaseType 2 Diabetes Mellitus

Interventions

DRUG

Finerenone (Kerendia, BAY 948862)

Retrospective analysis using secondary data collection from various sources

DRUG

Sodium-glucose cotransporter 2 inhibitors (SGLT2i)

Retrospective analysis using secondary data collection from various sources

DRUG

Glucagon-like peptide-1 receptor agonists (GLP 1 RA)

Retrospective analysis using secondary data collection from various sources

DRUG

Steroidal mineral corticoid receptor antagonists (sMRA)

Retrospective analysis using secondary data collection from various sources

DRUG

Non-steroidal mineral corticoid receptor antagonists (nsMRA)

Retrospective analysis using secondary data collection from various sources

Trial Locations (5)

55344

Optum CDM, Eden Prairie

Unknown

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY